Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proliferative Phase01:20

Proliferative Phase

1.4K
The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
1.4K
Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Group Therapy01:26

Group Therapy

446
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
446
Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Behavior Therapy01:22

Behavior Therapy

713
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
713
Drug Therapy01:28

Drug Therapy

298
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
298

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Percutaneous Native Kidney Biopsy Complications in Diabetic Patients in the TRIDENT Cohort.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Beyond Genotype: Multidomain Biomarker-Integrated Risk Scores Reveal Prognostic phenotypes Among Individuals with High-Risk <i>APOL1</i> Genotypes.

medRxiv : the preprint server for health sciences·2026
Same author

Podocyte-Targeted Therapy in Focal Segmental Glomerulosclerosis: Insights From a Phase 2 Trial of TRPC6 Inhibition.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Rhabdomyolysis and Acute Kidney Injury after the New York City Marathon.

Nephron·2026
Same author

Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Kidney international·2026
Same author

Communication leading to injury: podocyte-derived fibrillin-1 induces mesangial cell activation and proliferation through EGFR signaling.

Kidney international·2026

Related Experiment Video

Updated: Feb 4, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

668

Therapy for Proliferative Lupus Nephritis.

Kristin Meliambro1, Kirk N Campbell1, Miriam Chung1

  • 1Division of Nephrology, Icahn School of Medicine at Mount Sinai, Box 1243, One Gustave L. Levy Place, New York, NY 10029, USA.

Rheumatic Diseases Clinics of North America
|October 3, 2018
PubMed
Summary

Lupus nephritis treatment requires immunosuppressants like cyclophosphamide or mycophenolate mofetil. New therapies targeting key pathways are being investigated to improve remission rates in proliferative lupus nephritis.

Keywords:
ImmunosuppressiveLupus nephritisProliferativeSLETreatment

More Related Videos

Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
12:28

Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies

Published on: March 12, 2022

4.3K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.7K

Related Experiment Videos

Last Updated: Feb 4, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

668
Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
12:28

Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies

Published on: March 12, 2022

4.3K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.7K

Area of Science:

  • Nephrology
  • Immunology
  • Rheumatology

Background:

  • Proliferative lupus nephritis necessitates prompt immunosuppressive therapy.
  • Cyclophosphamide is a well-established treatment, while mycophenolate mofetil offers an alternative without infertility risks.
  • Current treatments yield suboptimal remission rates, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To review established and novel therapeutic options for proliferative lupus nephritis.
  • To discuss clinical trials supporting current treatment regimens.
  • To explore emerging agents targeting key pathogenic pathways in lupus nephritis.

Main Methods:

  • Review of clinical trial findings for established induction and maintenance therapies.
  • Analysis of ongoing studies investigating novel therapeutic agents.
  • Examination of research on molecular targets and pathways in lupus nephritis pathogenesis.

Main Results:

  • Established treatments like cyclophosphamide and mycophenolate mofetil demonstrate efficacy but have limitations.
  • Mycophenolate mofetil provides an alternative induction and maintenance option without the risk of infertility.
  • Suboptimal remission rates underscore the need for more effective treatments.

Conclusions:

  • Established immunosuppressive therapies are crucial for proliferative lupus nephritis management.
  • Novel therapeutic investigations targeting specific pathways show promise for improving patient outcomes.
  • Continued research is essential to develop superior treatment options for lupus nephritis.